Effectiveness of Sildenafil in Treating Erectile Dysfunction in Diabetic Men
Abstract
Diabetes mellitus (DM) is commonly associated with erectile dysfunction (ED), which can negatively affect sexual function and quality of life. Sildenafil, a phosphodiesterase type 5 (PDE-5) inhibitor, is frequently used to manage ED. This meta-analysis aimed to evaluate the available evidence regarding the efficacy and safety of sildenafil for erectile dysfunction associated with diabetes.
Electronic databases were searched to identify randomized controlled trials (RCTs) investigating sildenafil therapy in individuals with diabetes-related ED. Relevant data were extracted, and the methodological quality of the included studies was assessed. Appropriate effect measures with 95% confidence intervals (CIs) were used to evaluate treatment outcomes.
Eight RCTs involving a total of 1,172 participants met the eligibility criteria. Compared with placebo, sildenafil produced a significant improvement in overall sexual performance among individuals with diabetes-associated ED. The relative risk (RR) for a positive response to the global efficacy question was 3.99 (95% CI: 2.58–6.18). Treatment discontinuation due to adverse events occurred in 2.4% of participants receiving sildenafil, with an RR of 2.67 (95% CI: 0.74–9.62).
Overall, the available evidence indicates that sildenafil is an effective treatment for erectile dysfunction associated with diabetes mellitus and has an acceptable safety profile.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 1,172 participants or records.
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.